Jonas Bochem
Overview
Explore the profile of Jonas Bochem including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
79
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gaissler A, Bochem J, Spreuer J, Ottmann S, Martens A, Amaral T, et al.
J Immunother Cancer
. 2023 Jun;
11(6).
PMID: 37286306
Background: The need for reliable clinical biomarkers to predict which patients with melanoma will benefit from immune checkpoint blockade (ICB) remains unmet. Several different parameters have been considered in the...
2.
Gaissler A, Sundebo Meldgaard T, Heeke C, Babaei S, Tvingsholm S, Bochem J, et al.
Front Immunol
. 2022 Jul;
13:906352.
PMID: 35874702
Immune checkpoint blockade (ICB) is standard-of-care for patients with metastatic melanoma. It may re-invigorate T cells recognizing tumors, and several tumor antigens have been identified as potential targets. However, little...
3.
Stagno M, Schmidt A, Bochem J, Urla C, Handgretinger R, Cabanillas Stanchi K, et al.
Br J Cancer
. 2022 Jul;
127(7):1324-1331.
PMID: 35864157
Background: Neuroblastoma (NB) is the most common paediatric extracranial solid malignancy. We analysed the role of the epitope detection in monocytes (EDIM) technique for liquid biopsy in NB patients. Methods:...
4.
Bochem J, Zelba H, Spreuer J, Amaral T, Wagner N, Gaissler A, et al.
J Immunother Cancer
. 2021 Dec;
9(12).
PMID: 34933966
Background: Anti-programmed cell death protein 1 (PD-1) antibodies are now routinely administered for metastatic melanoma and for increasing numbers of other cancers, but still only a fraction of patients respond....
5.
Beucke N, Wesch D, Oberg H, Peters C, Bochem J, Weide B, et al.
J Leukoc Biol
. 2020 Jan;
107(6):1097-1105.
PMID: 31967358
Dissection of the role and function of human γδ T cells and their heterogeneous subsets in cancer, inflammation, and auto-immune diseases is a growing and dynamic research field of increasing...
6.
Bochem J, Zelba H, Amaral T, Spreuer J, Soffel D, Eigentler T, et al.
PLoS One
. 2019 Aug;
14(8):e0221301.
PMID: 31419253
Immune checkpoint blockade with anti-PD-1 antibodies is showing great promise for patients with metastatic melanoma and other malignancies, but despite good responses by some patients who achieve partial or complete...
7.
Stuhler V, Maas J, Bochem J, Anselmo da Costa I, Todenhofer T, Stenzl A, et al.
World J Urol
. 2018 Oct;
37(9):1773-1784.
PMID: 30374610
Introduction: The survival of patients with metastatic urothelial cancer (mUC) is poor. During the last 40 years, chemotherapy was the predominant treatment modality for mUC. The discovery of the immune...
8.
Zelba H, Bochem J, Pawelec G, Garbe C, Wistuba-Hamprecht K, Weide B
Cancer Immunol Immunother
. 2018 Sep;
67(12):1845-1851.
PMID: 30218171
Increasing numbers of trials employing anti-PD-1 immunotherapy emphasize the requirement for predictive biomarkers of clinical response. Many studies examine the cell surface expression of PD-1 and other key regulators of...
9.
Stagno M, Zacharopoulou N, Bochem J, Tsapara A, Pelzl L, Al-Maghout T, et al.
Cell Physiol Biochem
. 2017 Jul;
42(4):1366-1376.
PMID: 28704809
Background/aims: Istaroxime is a validated inotropic Na+/K+ ATPase inhibitor currently in development for the treatment of various cardiac conditions. Recent findings established that this steroidal drug exhibits potent apoptotic responses...